Cart summary

You have no items in your shopping cart.

HSP90-IN-13

SKU: orb1686835

Description

HSP90-IN-13 is a potent, broad-spectrum HSP90 inhibitor (IC50 = 25.07 nM) with additional activity against EGFR, VEGFR-2, and Topoisomerase II. It induces G2/M cell cycle arrest and triggers mitochondrial apoptosis in MCF-7 breast cancer cells, supporting its investigation in oncology research for in vitro mechanistic studies.

Research Area

Cardiovascular Research, Cell Biology, Metabolism Research, Molecular Biology, Signal Transduction

Images & Validation

Key Properties

CAS Number2446055-29-2
MW483.54
FormulaC26H21N5O3S
SMILESC(N1C(SCC2=CN(N=N2)C3=CC(C(O)=O)=CC=C3)=NC=4C(C1=O)=CC(C)=CC4)C5=CC=CC=C5
TargetOthers,Topoisomerase,HSP,EGFR,VEGFR,Apoptosis

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

HSP90-IN-13 (orb1686835)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%